NASDAQ: CBIO
Crescent Biopharma Inc Stock Ownership - Who owns Crescent Biopharma?

Insider buying vs selling

Have Crescent Biopharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Fairmount Funds Management LLCDirector2025-12-041,360,000$13.41
$18.24MBuy

1 of 1

CBIO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CBIO insiders and whales buy or sell their stock.

CBIO Shareholders

What type of owners hold Crescent Biopharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Scott D. Sandell50.98%14,056,571$280.71MInsider
Peter J. Barris47.81%13,182,418$263.25MInsider
M. James Barrett47.81%13,182,418$263.25MInsider
Siren LLC31.15%8,589,064$171.52MInsider
Invus Public Equities LP22.91%6,317,565$126.16MInsider
New Enterprise Associates 10 L P18.12%4,995,664$99.76MInsider
Fmr LLC14.99%4,133,514$82.55MInstitution
New Enterprise Associates 13 LP14.85%4,093,377$81.74MInsider
Bvf Inc9.97%2,748,763$54.89MInstitution
Fairmount Funds Management LLC9.97%2,747,866$54.87MInstitution

1 of 3

CBIO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CBIO26.11%73.89%Net Buying
ALT35.27%32.64%Net BuyingNet Buying
ACHV20.85%16.84%Net Selling
IMMX49.67%17.82%Net Buying
ANL9.55%0.00%

Crescent Biopharma Stock Ownership FAQ

Who owns Crescent Biopharma?

Crescent Biopharma (NASDAQ: CBIO) is owned by 93.83% institutional shareholders, 265.58% Crescent Biopharma insiders, and 0.00% retail investors. Scott D. Sandell is the largest individual Crescent Biopharma shareholder, owning 14.06M shares representing 50.98% of the company. Scott D. Sandell's Crescent Biopharma shares are currently valued at $280.71M.

If you're new to stock investing, here's how to buy Crescent Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.